全球非侵入性癌症诊断市场

预计到 2030 年全球非侵入性癌症诊断市场规模将达 2,243 亿美元

全球非侵入性癌症诊断市场规模预计在2024年为1564亿美元，预计到2030年将达到2243亿美元，在2024-2030年的分析期内，复合年增长率为6.2%。免疫化学是本报告分析的细分领域之一，预计其复合年增长率为8.1%，到分析期结束时规模将达到1005亿美元。临床微生物学细分领域在分析期间的复合年增长率预计为4.0%。

美国市场规模估计为 426 亿美元，中国市场预计复合年增长率为 10.1%

美国非侵入性癌症诊断市场规模预计在2024年达到426亿美元。作为世界第二大经济体，中国预计到2030年市场规模将达到468亿美元，在2024-2030年的分析期间内，复合年增长率为10.1%。其他值得关注的区域市场包括日本和加拿大，预计在分析期间内，这两个市场的复合年增长率分别为2.9%和6.2%。在欧洲，预计德国市场的复合年增长率为4.1%。

全球非侵入性癌症诊断市场—主要趋势和驱动因素摘要

我们能否在不使用手术刀或切片穿刺针的情况下彻底改变癌症检测？

非侵入性癌症诊断技术正在改变肿瘤学格局，它能够透过体液和影像学检查（而非侵入性组织切片检查）实现恶性肿瘤的早期、精准检测和监测。这些技术利用血液、尿液、唾液和呼出气体中的生物标记物，使临床医生能够在早期阶段识别癌症，从而改善预后并降低手术风险。液态切片、循环肿瘤DNA (ctDNA) 分析、外泌体分析和分子成像等技术正在成为个人化肿瘤治疗的重要工具。这些方法将在筛检癌、卵巢和肺癌等难以取得的癌症方面发挥特别重要的作用，因为传统的切片检查在这些癌症中产量比率高、获益低。

基因组学、蛋白质组学和先进成像技术的融合，将非侵入性诊断的范围从简单的检测拓展到肿瘤分型、突变分析和即时疗效监测。例如，液态切片不仅用于早期癌症诊断，还用于在治疗期间识别抗药性突变，并追踪治疗后的微量残存疾病。这些方法具有重复检测、减轻患者不适和快速治疗的优势，符合以患者为中心的精准癌症治疗趋势。这些方法正越来越多地被纳入全球领先肿瘤中心的临床指南和研究设计中。

为什么全球对非侵入性快速诊断的需求日益增加？

受人口、临床和经济等多种因素的影响，对非侵入性诊断的需求正在激增。全球癌症发病率上升、人口老化以及人们对早期发现益处的认识不断提高，这些因素正在推动医疗保健系统实施扩充性、无创伤且经济高效的筛检工具。各国政府和公共卫生计画正在优先考虑非侵入性诊断，以扩大基于人群的筛检，尤其是在切片检查设施有限的中低收入国家。这些工具提供了在症状出现之前进行早期疗育的可能性，从而减轻晚期癌症治疗的负担并提高存活率。

在高所得国家，向基于价值的医疗模式的转变正迫使支付方和医疗服务提供者支持旨在减少不必要程序、住院和延误治疗的诊断解决方案。非侵入性检测能够有效地进行风险分层，并减少对高成本影像检查和探查性手术的依赖。此外，患者偏好也日益影响临床选择。微创治疗方案在那些不愿忍受疼痛、併发症和反覆侵入性监测的患者族群中越来越受欢迎。从肺癌的呼吸分析到大肠直肠癌的粪便DNA检测，各种平台正逐渐受到寻求便捷居家诊断解决方案的患者的青睐。

最尖端科技如何提高诊断的准确性和可近性？

次世代定序(NGS)、数位 PCR、微流体和机器学习等新兴技术正在提高非侵入性癌症诊断的敏感度、特异性和扩充性。基于 NGS 的液态切片如今只需 1 毫升血浆即可检测单核苷酸变异、拷贝数变异和融合基因，从而实现全面的肿瘤分析。数位 PCR 平台可对 ctDNA 进行超灵敏定量分析，并以无与伦比的精度支援长期监测。微流体晶片已被开发用于即时分离循环性肿瘤细胞(CTC) 和外泌体，支援分散式检查和照护现场诊断。

人工智慧 (AI) 和数据分析正应用于放射组学和病理成像，以从非侵入性扫描中提取深层表型特征。放射基因组学能够整合影像生物标记和基因组数据，从而非侵入性地推断肿瘤的分子亚型。云端连接诊断平台使临床医生能够透过连续血液检测和影像扫描远端监测病情进展和治疗反应。新兴企业和医疗科技创新者正专注于多重检测、穿戴式感测器和家用诊断套件，以实现普及化，并实现对高风险族群的主动癌症监测。

推动非侵入性癌症诊断市场快速成长的因素是什么？

非侵入性癌症诊断市场的成长受到几股重塑全球肿瘤生态系统的强大力量的推动。其中一个关键驱动因素是精准医疗的日益普及，其中早期非侵入性检测是治疗计划、伴随诊断和即时监测的基石。生物製药公司越来越多地与诊断公司合作，共同开发用于指南标靶治疗选择和临床试验入组的检测方法，从而加速商业化并获得报销支持。

液态切片和非侵入性检测获得监管机构、临床协会和付款方的认可也是关键的成长动力。美国食品药物管理局 (FDA) 早期核准了基于 ctDNA 的伴随诊断产品，美国医疗保险和医疗补助服务中心 (CMS) 也对多项癌症检测测试做出了有利的报销决定，这些倡议检验了市场潜力并刺激了投资。临床试验和真实世界研究持续证明这些工具在检测早期癌症、追踪抗药性突变和改善治疗效果的效用。同时，创业投资的流入和併购活性化正在推动技术创新和全球市场的扩张。

多组体学平台、人工智慧增强诊断和分散式样本收集的日益普及也降低了成本门槛，将非侵入性癌症诊断带入门诊、基层医疗诊所，甚至患者家中。随着癌症治疗逐渐转向以预防、监测和生存为重点的持续护理模式，非侵入性诊断将在将癌症从末期疾病转变为可控的慢性疾病方面发挥核心作用。凭藉强大的研发开发平臺、有利的政策环境和强劲的临床发展势头，癌症市场预计将在各个适应症和地区实现指数级增长。

部分

产品类型（免疫化学、临床微生物学、就地检验、血液学、其他产品类型）、癌症类型（肺癌、乳癌、固体癌、血癌、卵巢癌、其他癌症类型）、最终用户（医院和诊所、诊断中心、门诊诊所、其他最终用户）

受访公司范例（值得关注的34家公司）

• Biocept, Inc.
• Caris Life Sciences
• Datar Cancer Genetics
• DELFI Diagnostics
• Exact Sciences Corporation
• Foundation Medicine
• Freenome Holdings, Inc.
• Guardant Health, Inc.
• iCAD, Inc.
• Illumina, Inc.
• Lucence Health Inc.
• Myriad Genetics, Inc.
• Natera, Inc.
• Oncocyte Corporation
• Pacific Edge Ltd.
• QIAGEN NV
• Roche Diagnostics
• SAGA Diagnostics AB
• Thermo Fisher Scientific
• Veracyte, Inc.

关税影响係数

全球产业分析师根据公司总部所在国家、製造地、进出口（成品和原始OEM）来预测其竞争地位的变化。这种复杂且多面向的市场动态预计将以多种方式影响竞争对手，包括人为提高销货成本、盈利下降、供应链重组以及其他微观和宏观市场动态。

全球产业分析师密切关注来自全球顶尖首席经济学家（14,949位）、智库（62家）以及贸易和产业协会（171家）的专家的意见，以评估其对生态系统的影响并应对新的市场现实。我们追踪了来自每个主要国家的专家和经济学家对关税及其对本国影响的看法。

全球产业分析师预计，这场动盪将在未来2-3个月内逐渐平息，新的世界秩序将更加清晰地建立。全球产业分析师正在即时追踪这些事态发展。

2025年4月：谈判阶段

在4月的报告中，我们将探讨关税对全球整体市场的影响，并提供区域市场调整。我们的预测是基于历史数据和不断变化的市场影响因素。

2025年7月：最终关税调整

在各国宣布最终重置后，客户将在 7 月收到免费更新，最终更新将包含明确的关税影响分析。

相互和双边贸易及关税影响分析：

美国<>中国<>墨西哥<>加拿大<>欧盟<>日本<>印度<>其他176个国家

领先的产业经济学家：全球产业分析师知识库追踪了 14,949 位经济学家，其中包括来自民族国家、智库、贸易和产业协会、大型企业以及各领域专家的最具影响力的首席经济学家，他们共用了这场前所未有的全球经济状况模式转移的影响。我们超过 16,491 份报告大多遵循基于里程碑的两阶段发布计划。

目录

第一章调查方法

第二章执行摘要

• 市场概览
• 主要企业
• 市场趋势和驱动因素
• 全球市场展望

第三章市场分析

• 美国
• 加拿大
• 日本
• 中国
• 欧洲
• 法国
• 德国
• 义大利
• 英国
• 西班牙
• 俄罗斯
• 其他欧洲国家
• 亚太地区
• 澳洲
• 印度
• 韩国
• 其他亚太地区
• 拉丁美洲
• 阿根廷
• 巴西
• 墨西哥
• 其他拉丁美洲
• 中东
• 伊朗
• 以色列
• 沙乌地阿拉伯
• 阿拉伯聯合大公国
• 其他中东地区
• 非洲

第四章 竞赛

Global Non-Invasive Cancer Diagnostics Market to Reach US$224.3 Billion by 2030

The global market for Non-Invasive Cancer Diagnostics estimated at US$156.4 Billion in the year 2024, is expected to reach US$224.3 Billion by 2030, growing at a CAGR of 6.2% over the analysis period 2024-2030. Immunochemistry, one of the segments analyzed in the report, is expected to record a 8.1% CAGR and reach US$100.5 Billion by the end of the analysis period. Growth in the Clinical Microbiology segment is estimated at 4.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$42.6 Billion While China is Forecast to Grow at 10.1% CAGR

The Non-Invasive Cancer Diagnostics market in the U.S. is estimated at US$42.6 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$46.8 Billion by the year 2030 trailing a CAGR of 10.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.9% and 6.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.1% CAGR.

Global Non-Invasive Cancer Diagnostics Market - Key Trends & Drivers Summarized

Can Cancer Detection Be Revolutionized Without a Scalpel or Biopsy Needle?

Non-invasive cancer diagnostics are transforming the oncology landscape by enabling early, accurate detection and monitoring of malignancies through bodily fluids and imaging, rather than invasive tissue biopsies. Leveraging biomarkers found in blood, urine, saliva, and exhaled breath, these technologies allow clinicians to identify cancers at nascent stages, improving prognosis and reducing procedural risks. Techniques such as liquid biopsies, circulating tumor DNA (ctDNA) analysis, exosome profiling, and molecular imaging are emerging as critical tools in personalized oncology. These approaches are especially impactful in screening hard-to-access cancers like pancreatic, ovarian, and lung, where traditional biopsies pose high risk and low yield.

The convergence of genomics, proteomics, and advanced imaging has expanded the scope of non-invasive diagnostics beyond mere detection to encompass tumor typing, mutation profiling, and real-time treatment response monitoring. Liquid biopsies, for instance, are being used not only for initial cancer diagnosis but also for identifying resistance mutations during therapy and tracking minimal residual disease post-treatment. These modalities offer advantages in repeat testing, reduced patient discomfort, and faster turnaround, aligning with the growing emphasis on patient-centric and precision-based cancer care. They are increasingly being integrated into clinical guidelines and trial designs across major oncology centers worldwide.

Why Is the Demand for Less Invasive, Faster Diagnostics Gaining Ground Globally?

The demand for non-invasive diagnostics is surging due to a combination of demographic, clinical, and economic factors. Globally rising cancer incidence, aging populations, and growing awareness of the benefits of early detection are prompting health systems to adopt screening tools that are scalable, non-traumatic, and cost-effective. Governments and public health programs are prioritizing non-invasive diagnostics to expand population-based screening, especially in low- and middle-income countries where access to surgical biopsy facilities remains limited. These tools offer the possibility of early intervention before symptom onset, thereby reducing the burden of late-stage cancer treatment and improving survival rates.

In high-income countries, the shift toward value-based care models is compelling payers and providers to favor diagnostic solutions that reduce unnecessary procedures, hospitalizations, and treatment delays. Non-invasive tests enable efficient risk stratification and reduce the dependence on high-cost imaging or exploratory surgery. Furthermore, patient preference is increasingly influencing clinical choices-minimally invasive options are gaining traction among individuals wary of pain, complications, and repeated invasive monitoring. From lung cancer breath analysis to stool-DNA testing for colorectal cancer, diverse platforms are being embraced by patients seeking accessible, home-based diagnostic solutions.

How Are Cutting-Edge Technologies Elevating Diagnostic Precision and Accessibility?

Advanced technologies such as next-generation sequencing (NGS), digital PCR, microfluidics, and machine learning are enhancing the sensitivity, specificity, and scalability of non-invasive cancer diagnostics. NGS-based liquid biopsies now detect single nucleotide variants, copy number alterations, and fusion genes from as little as 1 mL of plasma, enabling comprehensive tumor profiling. Digital PCR platforms offer ultra-sensitive quantification of ctDNA, supporting longitudinal monitoring with unmatched precision. Microfluidic chips are being developed to isolate circulating tumor cells (CTCs) and exosomes in real time, supporting decentralized testing and point-of-care diagnostics.

Artificial intelligence (AI) and data analytics are being applied to radiomics and pathology imaging to extract deep phenotypic features from non-invasive scans. Radiogenomics is enabling the integration of imaging biomarkers with genomic data to non-invasively infer molecular subtypes of tumors. Cloud-connected diagnostic platforms allow clinicians to remotely monitor disease progression and therapy response using serial blood tests or imaging scans. Startups and medtech innovators are focusing on multiplexed assays, wearable sensors, and at-home diagnostic kits, democratizing access and enabling proactive cancer surveillance for high-risk populations.

What’s Driving the Breakneck Growth in the Non-Invasive Cancer Diagnostics Market?

The growth in the non-invasive cancer diagnostics market is driven by several powerful forces that are reshaping the global oncology ecosystem. A key driver is the growing adoption of precision medicine, where early, non-invasive detection is foundational to treatment planning, companion diagnostics, and real-time monitoring. Biopharma companies are increasingly collaborating with diagnostic firms to co-develop assays that guide targeted therapy selection and clinical trial enrollment, accelerating commercialization and reimbursement support.

Another crucial growth catalyst is the rising acceptance of liquid biopsies and non-invasive tests by regulatory bodies, clinical societies, and payers. The FDA’s accelerated approvals of ctDNA-based companion diagnostics and CMS’s favorable reimbursement decisions for multi-cancer detection tests have validated market potential and driven investment. Clinical trials and real-world studies continue to demonstrate the utility of these tools in detecting early-stage cancers, tracking resistance mutations, and improving treatment outcomes. In parallel, rising venture capital inflows and M&A activity are fueling innovation and global market expansion.

The expanding use of multi-omics platforms, AI-enhanced diagnostics, and decentralized sample collection is also reducing cost barriers and bringing non-invasive cancer diagnostics to outpatient settings, primary care clinics, and even patients’ homes. As oncology transitions into a continuous-care model focused on prevention, monitoring, and survivorship, non-invasive diagnostics will play a central role in transforming cancer from a late-stage crisis to a manageable chronic condition. With robust R&D pipelines, supportive policy landscapes, and strong clinical momentum, the market is poised for exponential growth across indications and geographies.

SCOPE OF STUDY:

The report analyzes the Non-Invasive Cancer Diagnostics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology, Other Product Types); Cancer Type (Lung Cancer, Breast Cancer, Solid Tumors, Blood Cancer, Ovarian Cancer, Other Cancer Types); End-Use (Hospitals & Clinics, Diagnostic Centers, Ambulatory Care, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

• Biocept, Inc.
• Caris Life Sciences
• Datar Cancer Genetics
• DELFI Diagnostics
• Exact Sciences Corporation
• Foundation Medicine
• Freenome Holdings, Inc.
• Guardant Health, Inc.
• iCAD, Inc.
• Illumina, Inc.
• Lucence Health Inc.
• Myriad Genetics, Inc.
• Natera, Inc.
• Oncocyte Corporation
• Pacific Edge Ltd.
• QIAGEN N.V.
• Roche Diagnostics
• SAGA Diagnostics AB
• Thermo Fisher Scientific
• Veracyte, Inc.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Non-Invasive Cancer Diagnostics - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Surge in Early Detection Initiatives and Screening Programs Drives Demand for Non-Invasive Cancer Diagnostics
  • Growing Preference for Liquid Biopsy Over Surgical Procedures Strengthens Market for Blood-Based Diagnostics
  • Advancements in cfDNA, ctDNA, and Exosome Analysis Propel Precision Oncology Adoption
  • Expansion of Multicancer Detection Panels Throws the Spotlight on Pan-Cancer Non-Invasive Testing Platforms
  • Rising Focus on Monitoring Minimal Residual Disease (MRD) Sustains Use in Post-Treatment Surveillance
  • Integration With AI-Powered Biomarker Analysis Enhances Predictive Accuracy and Risk Stratification
  • Increased Use in Companion Diagnostics Supports Targeted Therapy Matching for Personalized Cancer Care
  • OEM Partnerships With Pharma and Diagnostic Labs Accelerate Co-Development of Stratified Screening Solutions
  • Regulatory Approvals for Non-Invasive Assays Support Clinical Expansion in Lung, Breast, and Colorectal Cancer
  • Emergence of Home-Based Sample Collection Kits Expands Access and Convenience for High-Risk Populations
  • Investment in Cancer Moonshot and Global Screening Programs Drives Research Funding for Non-Invasive Tools
  • Challenges in Sensitivity and Specificity of Early-Stage Detection Propel Innovation in Signal Amplification Techniques
  • Expansion of Reimbursement Frameworks in High-Income Countries Enhances Patient Access to Advanced Testing
  • Use of Urine, Saliva, and Breath Biomarkers Expands Sample Collection Modalities
  • Rising Incidence of Cancer in Aging Populations Supports Demand for Less Invasive Monitoring Methods
  • Technological Advancements in NGS and PCR-Based Platforms Reduce Turnaround Time and Cost Per Test
  • Focus on Longitudinal Disease Tracking and Recurrence Prediction Enhances Market for Serial Testing Solutions
  • Emergence of Wearable Biosensor Technologies Opens Future Pathways for Continuous Cancer Monitoring
  • Data Integration With EHR and Oncology Informatics Platforms Supports Clinical Decision-Making
  • OEM Strategies to Expand in Emerging Markets Strengthen Geographic Penetration of Non-Invasive Diagnostics
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Non-Invasive Cancer Diagnostics Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Non-Invasive Cancer Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Non-Invasive Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Immunochemistry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Immunochemistry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Immunochemistry by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Clinical Microbiology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Clinical Microbiology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Clinical Microbiology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Point of Care Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Point of Care Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Point of Care Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Hematology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Hematology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Hematology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Other Product Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Ovarian Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Ovarian Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Ovarian Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Other Cancer Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Other Cancer Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Other Cancer Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Lung Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Breast Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Solid Tumors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Solid Tumors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Solid Tumors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Blood Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Blood Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Blood Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: World 15-Year Perspective for Hospitals & Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 41: World Recent Past, Current & Future Analysis for Diagnostic Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 42: World Historic Review for Diagnostic Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: World 15-Year Perspective for Diagnostic Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 44: World Recent Past, Current & Future Analysis for Ambulatory Care by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 45: World Historic Review for Ambulatory Care by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: World 15-Year Perspective for Ambulatory Care by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 47: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 48: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Non-Invasive Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 50: USA Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: USA Historic Review for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: USA 15-Year Perspective for Non-Invasive Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 53: USA Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: USA Historic Review for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: USA 15-Year Perspective for Non-Invasive Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer for the Years 2015, 2025 & 2030
  • TABLE 56: USA Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: USA Historic Review for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: USA 15-Year Perspective for Non-Invasive Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 59: Canada Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Canada Historic Review for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: Canada 15-Year Perspective for Non-Invasive Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 62: Canada Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Canada Historic Review for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: Canada 15-Year Perspective for Non-Invasive Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer for the Years 2015, 2025 & 2030
  • TABLE 65: Canada Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Canada Historic Review for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: Canada 15-Year Perspective for Non-Invasive Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses for the Years 2015, 2025 & 2030
• JAPAN
  • Non-Invasive Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 68: Japan Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Japan Historic Review for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: Japan 15-Year Perspective for Non-Invasive Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 71: Japan Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Japan Historic Review for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: Japan 15-Year Perspective for Non-Invasive Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer for the Years 2015, 2025 & 2030
  • TABLE 74: Japan Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Japan Historic Review for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: Japan 15-Year Perspective for Non-Invasive Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses for the Years 2015, 2025 & 2030
• CHINA
  • Non-Invasive Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 77: China Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: China Historic Review for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: China 15-Year Perspective for Non-Invasive Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 80: China Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: China Historic Review for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: China 15-Year Perspective for Non-Invasive Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer for the Years 2015, 2025 & 2030
  • TABLE 83: China Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: China Historic Review for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: China 15-Year Perspective for Non-Invasive Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses for the Years 2015, 2025 & 2030
• EUROPE
  • Non-Invasive Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 86: Europe Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 87: Europe Historic Review for Non-Invasive Cancer Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: Europe 15-Year Perspective for Non-Invasive Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 89: Europe Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Europe Historic Review for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: Europe 15-Year Perspective for Non-Invasive Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 92: Europe Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Europe Historic Review for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: Europe 15-Year Perspective for Non-Invasive Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer for the Years 2015, 2025 & 2030
  • TABLE 95: Europe Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Europe Historic Review for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: Europe 15-Year Perspective for Non-Invasive Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses for the Years 2015, 2025 & 2030
• FRANCE
  • Non-Invasive Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 98: France Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: France Historic Review for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: France 15-Year Perspective for Non-Invasive Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 101: France Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: France Historic Review for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: France 15-Year Perspective for Non-Invasive Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer for the Years 2015, 2025 & 2030
  • TABLE 104: France Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: France Historic Review for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: France 15-Year Perspective for Non-Invasive Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses for the Years 2015, 2025 & 2030
• GERMANY
  • Non-Invasive Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 107: Germany Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Germany Historic Review for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: Germany 15-Year Perspective for Non-Invasive Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 110: Germany Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Germany Historic Review for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: Germany 15-Year Perspective for Non-Invasive Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer for the Years 2015, 2025 & 2030
  • TABLE 113: Germany Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Germany Historic Review for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: Germany 15-Year Perspective for Non-Invasive Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 116: Italy Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Italy Historic Review for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: Italy 15-Year Perspective for Non-Invasive Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 119: Italy Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Italy Historic Review for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: Italy 15-Year Perspective for Non-Invasive Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer for the Years 2015, 2025 & 2030
  • TABLE 122: Italy Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Italy Historic Review for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: Italy 15-Year Perspective for Non-Invasive Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Non-Invasive Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 125: UK Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: UK Historic Review for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: UK 15-Year Perspective for Non-Invasive Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 128: UK Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: UK Historic Review for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: UK 15-Year Perspective for Non-Invasive Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer for the Years 2015, 2025 & 2030
  • TABLE 131: UK Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: UK Historic Review for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: UK 15-Year Perspective for Non-Invasive Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 134: Spain Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Spain Historic Review for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Spain 15-Year Perspective for Non-Invasive Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 137: Spain Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Spain Historic Review for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Spain 15-Year Perspective for Non-Invasive Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer for the Years 2015, 2025 & 2030
  • TABLE 140: Spain Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Spain Historic Review for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Spain 15-Year Perspective for Non-Invasive Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 143: Russia Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Russia Historic Review for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Russia 15-Year Perspective for Non-Invasive Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 146: Russia Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Russia Historic Review for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Russia 15-Year Perspective for Non-Invasive Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer for the Years 2015, 2025 & 2030
  • TABLE 149: Russia Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Russia Historic Review for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: Russia 15-Year Perspective for Non-Invasive Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 152: Rest of Europe Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Rest of Europe Historic Review for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Rest of Europe 15-Year Perspective for Non-Invasive Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 155: Rest of Europe Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Rest of Europe Historic Review for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Rest of Europe 15-Year Perspective for Non-Invasive Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer for the Years 2015, 2025 & 2030
  • TABLE 158: Rest of Europe Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Rest of Europe Historic Review for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: Rest of Europe 15-Year Perspective for Non-Invasive Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Non-Invasive Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 162: Asia-Pacific Historic Review for Non-Invasive Cancer Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: Asia-Pacific 15-Year Perspective for Non-Invasive Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 164: Asia-Pacific Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Asia-Pacific Historic Review for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: Asia-Pacific 15-Year Perspective for Non-Invasive Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 167: Asia-Pacific Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Asia-Pacific Historic Review for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: Asia-Pacific 15-Year Perspective for Non-Invasive Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer for the Years 2015, 2025 & 2030
  • TABLE 170: Asia-Pacific Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Asia-Pacific Historic Review for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: Asia-Pacific 15-Year Perspective for Non-Invasive Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Non-Invasive Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 173: Australia Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Australia Historic Review for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: Australia 15-Year Perspective for Non-Invasive Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 176: Australia Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Australia Historic Review for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: Australia 15-Year Perspective for Non-Invasive Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer for the Years 2015, 2025 & 2030
  • TABLE 179: Australia Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Australia Historic Review for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: Australia 15-Year Perspective for Non-Invasive Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses for the Years 2015, 2025 & 2030
• INDIA
  • Non-Invasive Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 182: India Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: India Historic Review for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: India 15-Year Perspective for Non-Invasive Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 185: India Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: India Historic Review for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: India 15-Year Perspective for Non-Invasive Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer for the Years 2015, 2025 & 2030
  • TABLE 188: India Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: India Historic Review for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: India 15-Year Perspective for Non-Invasive Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 191: South Korea Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: South Korea Historic Review for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: South Korea 15-Year Perspective for Non-Invasive Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 194: South Korea Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: South Korea Historic Review for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: South Korea 15-Year Perspective for Non-Invasive Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer for the Years 2015, 2025 & 2030
  • TABLE 197: South Korea Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: South Korea Historic Review for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: South Korea 15-Year Perspective for Non-Invasive Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 200: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Rest of Asia-Pacific Historic Review for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Rest of Asia-Pacific 15-Year Perspective for Non-Invasive Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 203: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Rest of Asia-Pacific Historic Review for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Rest of Asia-Pacific 15-Year Perspective for Non-Invasive Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer for the Years 2015, 2025 & 2030
  • TABLE 206: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Rest of Asia-Pacific Historic Review for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Rest of Asia-Pacific 15-Year Perspective for Non-Invasive Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Non-Invasive Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 209: Latin America Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 210: Latin America Historic Review for Non-Invasive Cancer Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Latin America 15-Year Perspective for Non-Invasive Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 212: Latin America Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Latin America Historic Review for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Latin America 15-Year Perspective for Non-Invasive Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 215: Latin America Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Latin America Historic Review for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Latin America 15-Year Perspective for Non-Invasive Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer for the Years 2015, 2025 & 2030
  • TABLE 218: Latin America Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Latin America Historic Review for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: Latin America 15-Year Perspective for Non-Invasive Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 221: Argentina Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Argentina Historic Review for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: Argentina 15-Year Perspective for Non-Invasive Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 224: Argentina Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Argentina Historic Review for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: Argentina 15-Year Perspective for Non-Invasive Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer for the Years 2015, 2025 & 2030
  • TABLE 227: Argentina Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Argentina Historic Review for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: Argentina 15-Year Perspective for Non-Invasive Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 230: Brazil Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Brazil Historic Review for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: Brazil 15-Year Perspective for Non-Invasive Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 233: Brazil Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Brazil Historic Review for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: Brazil 15-Year Perspective for Non-Invasive Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer for the Years 2015, 2025 & 2030
  • TABLE 236: Brazil Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Brazil Historic Review for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: Brazil 15-Year Perspective for Non-Invasive Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 239: Mexico Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Mexico Historic Review for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: Mexico 15-Year Perspective for Non-Invasive Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 242: Mexico Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Mexico Historic Review for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: Mexico 15-Year Perspective for Non-Invasive Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer for the Years 2015, 2025 & 2030
  • TABLE 245: Mexico Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Mexico Historic Review for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: Mexico 15-Year Perspective for Non-Invasive Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 248: Rest of Latin America Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Rest of Latin America Historic Review for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: Rest of Latin America 15-Year Perspective for Non-Invasive Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 251: Rest of Latin America Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Rest of Latin America Historic Review for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: Rest of Latin America 15-Year Perspective for Non-Invasive Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer for the Years 2015, 2025 & 2030
  • TABLE 254: Rest of Latin America Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Rest of Latin America Historic Review for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Rest of Latin America 15-Year Perspective for Non-Invasive Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Non-Invasive Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 257: Middle East Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 258: Middle East Historic Review for Non-Invasive Cancer Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Middle East 15-Year Perspective for Non-Invasive Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 260: Middle East Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Middle East Historic Review for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Middle East 15-Year Perspective for Non-Invasive Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 263: Middle East Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Middle East Historic Review for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Middle East 15-Year Perspective for Non-Invasive Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer for the Years 2015, 2025 & 2030
  • TABLE 266: Middle East Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Middle East Historic Review for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Middle East 15-Year Perspective for Non-Invasive Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 269: Iran Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Iran Historic Review for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Iran 15-Year Perspective for Non-Invasive Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 272: Iran Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Iran Historic Review for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: Iran 15-Year Perspective for Non-Invasive Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer for the Years 2015, 2025 & 2030
  • TABLE 275: Iran Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Iran Historic Review for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: Iran 15-Year Perspective for Non-Invasive Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 278: Israel Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Israel Historic Review for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: Israel 15-Year Perspective for Non-Invasive Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 281: Israel Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Israel Historic Review for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: Israel 15-Year Perspective for Non-Invasive Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer for the Years 2015, 2025 & 2030
  • TABLE 284: Israel Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Israel Historic Review for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: Israel 15-Year Perspective for Non-Invasive Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 287: Saudi Arabia Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Saudi Arabia Historic Review for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: Saudi Arabia 15-Year Perspective for Non-Invasive Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 290: Saudi Arabia Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Saudi Arabia Historic Review for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: Saudi Arabia 15-Year Perspective for Non-Invasive Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer for the Years 2015, 2025 & 2030
  • TABLE 293: Saudi Arabia Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Saudi Arabia Historic Review for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: Saudi Arabia 15-Year Perspective for Non-Invasive Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 296: UAE Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: UAE Historic Review for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: UAE 15-Year Perspective for Non-Invasive Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 299: UAE Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: UAE Historic Review for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: UAE 15-Year Perspective for Non-Invasive Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer for the Years 2015, 2025 & 2030
  • TABLE 302: UAE Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: UAE Historic Review for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 304: UAE 15-Year Perspective for Non-Invasive Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 305: Rest of Middle East Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Rest of Middle East Historic Review for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 307: Rest of Middle East 15-Year Perspective for Non-Invasive Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 308: Rest of Middle East Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Rest of Middle East Historic Review for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 310: Rest of Middle East 15-Year Perspective for Non-Invasive Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer for the Years 2015, 2025 & 2030
  • TABLE 311: Rest of Middle East Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Rest of Middle East Historic Review for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 313: Rest of Middle East 15-Year Perspective for Non-Invasive Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses for the Years 2015, 2025 & 2030
• AFRICA
  • Non-Invasive Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 314: Africa Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 315: Africa Historic Review for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 316: Africa 15-Year Perspective for Non-Invasive Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 317: Africa Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 318: Africa Historic Review for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 319: Africa 15-Year Perspective for Non-Invasive Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer for the Years 2015, 2025 & 2030
  • TABLE 320: Africa Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 321: Africa Historic Review for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 322: Africa 15-Year Perspective for Non-Invasive Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses for the Years 2015, 2025 & 2030

IV. COMPETITION